MX9702932A - L-ribofuranosilnucleosidos. - Google Patents

L-ribofuranosilnucleosidos.

Info

Publication number
MX9702932A
MX9702932A MX9702932A MX9702932A MX9702932A MX 9702932 A MX9702932 A MX 9702932A MX 9702932 A MX9702932 A MX 9702932A MX 9702932 A MX9702932 A MX 9702932A MX 9702932 A MX9702932 A MX 9702932A
Authority
MX
Mexico
Prior art keywords
ribofuranosyl nucleosides
ribofuranosyl
nucleosides
mammals
beta
Prior art date
Application number
MX9702932A
Other languages
English (en)
Other versions
MXPA97002932A (es
Inventor
Alexander L Weis
Charles T Goodhue
Kirupathevy Shanmuganathan
Original Assignee
Genencor Int
Lipitek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor Int, Lipitek Inc filed Critical Genencor Int
Publication of MXPA97002932A publication Critical patent/MXPA97002932A/es
Publication of MX9702932A publication Critical patent/MX9702932A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invencion se relaciona a alfa y beta-L-ribofuranosilnucleosidos de Formula (i), a procesos para su preparacion, a compuestos farmacéuticas que los contienen, y a métodos para usarlos para tratar varias enfermedades en un mamífero.
MX9702932A 1994-10-24 1995-10-24 L-ribofuranosilnucleosidos. MX9702932A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/328,304 US5559101A (en) 1994-10-24 1994-10-24 L-ribofuranosyl nucleosides
US08328304 1994-10-24
PCT/US1995/013716 WO1996013512A2 (en) 1994-10-24 1995-10-24 L-ribofuranosyl nucleosides
USUS95/13716 1995-10-24

Publications (2)

Publication Number Publication Date
MXPA97002932A MXPA97002932A (es) 1998-04-01
MX9702932A true MX9702932A (es) 1998-04-30

Family

ID=23280423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702932A MX9702932A (es) 1994-10-24 1995-10-24 L-ribofuranosilnucleosidos.

Country Status (5)

Country Link
US (1) US5559101A (es)
EP (1) EP0788506A2 (es)
JP (1) JPH10507772A (es)
MX (1) MX9702932A (es)
WO (1) WO1996013512A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
EP1302474A1 (en) * 1996-10-16 2003-04-16 Ribapharm, Inc. Monocyclic L-nucleosides, analogs and uses thereof
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
EP1072607A3 (en) * 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses therof
PL187107B1 (pl) * 1996-10-16 2004-05-31 Icn Pharmaceuticals L-nukleozydy monocykliczne, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
CZ126799A3 (cs) * 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
US6090602A (en) 1998-02-18 2000-07-18 Promelas Research Corporation Levo-monosaccharide in a nucleoside analog for use as an anti-retroviral agent
CA2322494A1 (en) * 1998-03-11 1999-09-16 Annette M. Gero Novel nucleoside analogs and uses in treating disease
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
WO2000009531A2 (en) * 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
AU2004201286B2 (en) * 1998-08-10 2007-06-21 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
AU2011211428B2 (en) * 1998-08-10 2013-02-07 Centre National De La Recherche Scientifique Beta-L-2'-Deoxy Nucleosides for the treatment of Hepatitis B
AU2007216721B2 (en) * 1998-08-10 2011-05-19 Centre National De La Recherche Scientifique Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
RU2300381C2 (ru) * 1998-08-10 2007-06-10 Айденикс (Кайман) Лимитед β-L-2'-ДЕЗОКСИНУКЛЕОЗИДЫ ДЛЯ ЛЕЧЕНИЯ ГЕПАТИТА В
JP2002528554A (ja) 1998-11-05 2002-09-03 サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク Ｂ型肝炎ウイルス活性を持ったヌクレオシド
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
NZ514348A (en) * 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
EP1600452A3 (en) * 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
MXPA02004779A (es) * 1999-11-12 2004-07-01 Pharmasset Ltd Sintesis de 2'-desoxi-l-nucleosidos.
KR100385281B1 (ko) * 2000-02-15 2003-05-23 이승기 새로운 세포 주기 조절 인자 억제제
US6822089B1 (en) * 2000-03-29 2004-11-23 Isis Pharmaceuticals, Inc. Preparation of deoxynucleosides
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1348712B1 (en) * 2000-11-29 2011-05-04 Mitsui Chemicals, Inc. Processes and intermediates in the synthesis of L-thymidine
CN101250194B (zh) * 2000-11-29 2011-05-04 三井化学株式会社 L-核酸衍生物及其合成方法
AU2002351077A1 (en) * 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
WO2003053360A2 (en) 2001-12-20 2003-07-03 Pharmassett Ltd. Treatment of ebv and khsv infection and associated abnormal cellular proliferation
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
JP4173861B2 (ja) * 2002-09-13 2008-10-29 イデニクス（ケイマン）リミテツド 耐性ＨＢＶ菌株の治療のためのβ−Ｌ−２’−デオキシヌクレオシド及び併用療法
WO2004084453A2 (en) 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
US7595390B2 (en) * 2003-04-28 2009-09-29 Novartis Ag Industrially scalable nucleoside synthesis
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
EP1639121A4 (en) 2003-06-30 2008-04-16 Idenix Cayman Ltd SYNTHESIS OF BETA-L-2-DESOXYNUCLEOSIDES
DK1680137T3 (da) 2003-10-14 2013-02-18 Hoffmann La Roche Makrocyklisk carboxylsyre- og acylsulfonamidforbindelse som inhibitor af HCV-replikation
GB0400290D0 (en) * 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
BRPI0613796A2 (pt) 2005-06-07 2011-02-15 Univ Yale composicões farmacêuticas e seus usos, e métodos de tratamento de cáncer e outras condições ou estados patológicos, por meio do uso de clevudina (lfmau) e telbivudina (ldt)
CN108969767A (zh) * 2005-06-07 2018-12-11 耶鲁大学 使用克来夫定和替比夫定治疗癌症和其它病症或疾病状态的方法
US7951788B2 (en) 2005-12-02 2011-05-31 Yale University Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
WO2008063727A2 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
JP5663576B2 (ja) * 2010-07-06 2015-02-04 上西　秀則 神経突起伸長剤
CN102649788B (zh) * 2011-02-28 2015-03-25 四川大学 β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620185C3 (de) * 1966-03-02 1982-01-14 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen 5-Äthyl- und 5-Propyl-2'-deoxyuridin, Verfahren zur Herstellung dieser Verbindungen und diese Verbindungen enthaltende Arzneimittel
US3457255A (en) * 1967-05-17 1969-07-22 Syntex Corp Novel ribo and lyxo nucleoside derivatives and a process for their preparation
CS164401B1 (en) * 1971-10-07 1975-11-07 Jiri Beranek Method of 1-beta-d-arabinofuranosylcytosine's preparation
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
CA1135258A (en) * 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
EP0199451B1 (en) * 1985-03-16 1996-03-06 The Wellcome Foundation Limited Therapeutic nucleosides
CA1314875C (en) * 1985-05-15 1993-03-23 George Walter Koszalka Therapeutic nucleosides
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
KR960001372B1 (ko) * 1986-09-24 1996-01-26 예일 유니버시티 레트로비루스로 감염된 환자의 치료에 사용되는 2',3'-디디옥시사이티딘-2'-엔(2',3'-디디옥시-2',3'-디디하이드로사이티딘)의 항생물질
US4918056A (en) * 1986-10-14 1990-04-17 Health Research, Inc. (Roswell Park Division) 2-substituted arabinopyranosyl nucleosides and nucleotides
US4880782A (en) * 1986-11-21 1989-11-14 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Method of treating viral infections in humans and compositions therefor
SE8605503D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel medicinal use
IL85778A0 (en) * 1987-03-20 1988-09-30 Bristol Myers Co Production of 2',3'-dideoxynucleosides and certain such novel compounds
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
DE3900964A1 (de) * 1989-01-14 1990-07-19 Boehringer Mannheim Gmbh Neue nukleoside, verfahren zu deren herstellung sowie arzneimittel, die diese verbindungen enthalten
DD296281A5 (de) * 1990-07-01 1991-11-28 Akademie Der Wissenschaften Der Ddr,De Verfahren zur herstellung von neuen purinnukleosiden
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
WO1993003733A1 (en) * 1991-08-12 1993-03-04 Basco, Ltd. Syntheses, pharmaceutical composition and method of application of (2'-5') oligoadenylate analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
FR2709754B1 (fr) * 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.

Also Published As

Publication number Publication date
US5559101A (en) 1996-09-24
WO1996013512A3 (en) 1997-02-06
EP0788506A2 (en) 1997-08-13
WO1996013512A2 (en) 1996-05-09
JPH10507772A (ja) 1998-07-28

Similar Documents

Publication Publication Date Title
MX9702932A (es) L-ribofuranosilnucleosidos.
ATE179330T1 (de) Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
PT80079A (en) Process for the preparation of antiviral pharmaceutical preparations containing 2-diethylamino-2,2',6'-acetoxyxylidide (lidocaine)
MX9702926A (es) L-eritrosilnucleosidos.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
HK1010340A1 (en) The manufacture of compositions for the treatment of cell proliferation disorders
FR2651435B1 (es)
MX9702927A (es) L-piranosilnucleosidos.
MX9800049A (es) Antraquinonas mono- y disulfo-substituidas y su uso para el tratamiento de trastornos de la matriz del hueso.
ES8301244A1 (es) Procedimiento para la obtencion de derivados de sisomicina.
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
ES2016464A6 (es) Procedimiento para preparar derivados de 2', 5' -oligoadenilato.
DE3371515D1 (en) Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
IL88726A0 (en) Dihydrothienobenzodiazepinone derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof
IL104132A0 (en) Compositions for the treatment of mammalian diseases
UA37217C2 (uk) Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, фармацевтична композиція та проміжні сполуки
ZA843489B (en) 4-oxothiazolidin-2-ylidene-acetamide derivatives,processes for their preparation and their use in the combating of diseases of the central nervous system
MX9803791A (es) Intermediarios novedosos y su uso para preparar bisindolilmaleimidas n,n'-puenteadas.
ES8307811A1 (es) "procedimiento para la preparacion de nuevas imidazo 1,2-a pirimidinas".